nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.17650/2311-1267-2015-2-2-50-59nodgo-102Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ/ОБЗОРЫ ЛИТЕРАТУРЫORIGINAL INVESTIGATIONS/LITERATURE REVIEWSДИНАМИЧЕСКОЕ НАБЛЮДЕНИЕ ДЕТЕЙ ПОСЛЕ АЛЛОГЕННОЙ ТРАНСПЛАНТАЦИИ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОКDYNAMIC FOLLOW-UP OF CHILDREN AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONСкворцоваЮ. В.SkvortsovaYu. V.yuscvo@mail.ruБалашовД. Н.BalashovD. N.МасчанМ. А.MaschanM. A.ШелиховаЛ. Н.ShelikhovaL. N.МасчанА. А.MaschanA. A.ФГБУ «Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России; Россия, 117198, Москва, ул. Саморы Машела, 1РоссияFederal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia; 1 Samory Mashela St., Moscow, 117198, RussiaRussian Federation201529052015225059Copyright © Скворцова Ю.В., Балашов Д.Н., Масчан М.А., Шелихова Л.Н., Масчан А.А., 20152015Скворцова Ю.В., Балашов Д.Н., Масчан М.А., Шелихова Л.Н., Масчан А.А.Skvortsova Y.V., Balashov D.N., Maschan M.A., Shelikhova L.N., Maschan A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/102

В статье представлена схема мониторинга поздних осложнений у детей после проведения им трансплантации гемопоэтических стволовых клеток (ТГСК), а также особенности диспансеризации этих больных, как в специализированных, так и в лечебно-профилактических учреждениях по месту жительства. Приведено краткое описание поздних осложнений, их диагностики и лечения. Данная публикация предназначена для врачей, проводящих различные виды ТГСК, детских онкогематологов, гематологов, иммунологов и педиатров, осуществляющих наблюдение за детьми с онкогематологической и иммунологической патологией на местах, а также для врачей узкой специализации (эндокринологов, невропатологов, окулистов, гинекологов, кардиологов, гастроэнтерологов, нефрологов и др.).

The article contains the schedule of monitoring of late complications in children after hematopoietic stem cell transplantation (HSCT), аs well as peculiarities of the prophylactic examination of such patients both in specialized and general health facilities at the place of residence. There is a short description of late complications, its diagnostics and treatment. This publication is designed for physicians, carrying out several kinds of HSCT, children oncohematologists, hematologists, immunologists and pediatricians, performing the local follow-up of children, suffering with oncohematologic and immunologic diseases, as well as for medical specialists (endocrinologists, neuropathologist, oculists, gynecologists, cardiologists, gastroenterologists, nephrologists etc.).

трансплантация гемопоэтических стволовых клетокпоздние осложнения после трансплантации гемопоэтических стволовых клетокдетидиспансеризациядиагностикалечениенаблюдениеhematopoietic stem cell transplantationlate complications after hematopoietic stem cell transplantationchildrenprophylactic examinationdiagnosticstreatmentfollow-upReferencesThe EBMT Handbook. Наеmopoietic Stem Cell Transplantation. The revised 2012 Edition. J. Apperley, E. Carreras, E. Gluckman, T. Masszi (eds.).The EBMT Handbook. Наеmopoietic Stem Cell Transplantation. The revised 2012 Edition. J. Apperley, E. Carreras, E. Gluckman, T. Masszi (eds.).Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. Copyright 2008© Children,s Oncology Group. www. survivorshipguidelines.org. Version 3. October 2008.Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. Copyright 2008© Children,s Oncology Group. www. survivorshipguidelines.org. Version 3. October 2008.HCT Quick Reference Guidelines. Transplant Consultation and Posttransplant Care. Long-term survival guidelines. National Marrow Donor Program. June 2013.HCT Quick Reference Guidelines. Transplant Consultation and Posttransplant Care. Long-term survival guidelines. National Marrow Donor Program. June 2013.Recommended screening and preventive practices for long-term survivors after hematopoietic stem cell transplantation; Center for International Blood and Marrow Transplant Research (CIBMTR), American Society for Blood and Marrow Transplantation (ASBMT), European Group for Blood and Marrow Transplantation (EBMT), Asia-Pacific Blood and Marrow Transplantation Group (APBMT), Bone Marrow Transplant Society of Australia and New Zealand (BMTSANZ), East Mediterranean Blood and Marrow Transplantation Group (EMBMT). Co-published in Biol Blood Marrow Transplant 2012;18(3):337–41; and Hematol Oncol Stem Cell Ther 2012;5(1):1–30.Recommended screening and preventive practices for long-term survivors after hematopoietic stem cell transplantation; Center for International Blood and Marrow Transplant Research (CIBMTR), American Society for Blood and Marrow Transplantation (ASBMT), European Group for Blood and Marrow Transplantation (EBMT), Asia-Pacific Blood and Marrow Transplantation Group (APBMT), Bone Marrow Transplant Society of Australia and New Zealand (BMTSANZ), East Mediterranean Blood and Marrow Transplantation Group (EMBMT). Co-published in Biol Blood Marrow Transplant 2012;18(3):337–41; and Hematol Oncol Stem Cell Ther 2012;5(1):1–30.Румянцев А. Г., Масчан А. А. Трансплантация гемопоэтических стволовых клеток у детей. Руководство для врачей. М.: Медицинское информационное агентство, 2003. 909 с. [Rumyantsev A. G., Maschan A. A. Hematopoietic stem cell transplantation in children. M.: Medical Information Agency, 2003. 909 pp. (In Russ.)].Румянцев А. Г., Масчан А. А. Трансплантация гемопоэтических стволовых клеток у детей. Руководство для врачей. М.: Медицинское информационное агентство, 2003. 909 с. [Rumyantsev A. G., Maschan A. A. Hematopoietic stem cell transplantation in children. M.: Medical Information Agency, 2003. 909 pp. (In Russ.)].Storek J., Joseph A., Espino G. et al. Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. Blood 2001;98(13):3505–12.Storek J., Joseph A., Espino G. et al. Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. Blood 2001;98(13):3505–12.Styczynski J., Gil L. EBMT Paediatric Diseases Working Party. PreventionStyczynski J., Gil L. EBMT Paediatric Diseases Working Party. Preventionof infectious complications in pediatric HSCT. Bone Marrow Transplant 2008;42:S77–81.of infectious complications in pediatric HSCT. Bone Marrow Transplant 2008;42:S77–81.Kulkarni S., Powles R., Treleaven J. et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 2000;95(12):3683–6.Kulkarni S., Powles R., Treleaven J. et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 2000;95(12):3683–6.Sokos D. R., Berger M., Lazarus H. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002;8(3):117–30.Sokos D. R., Berger M., Lazarus H. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002;8(3):117–30.Patel S. R., Ortin M., Cohen B. J. et al. Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. Clin Infect Dis 2007;44(5):625–34.Patel S. R., Ortin M., Cohen B. J. et al. Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. Clin Infect Dis 2007;44(5):625–34.Ljungman P., Cordonnier C., Einsele H. et al. Vaccination of hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2009;44:521–6.Ljungman P., Cordonnier C., Einsele H. et al. Vaccination of hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2009;44:521–6.Filipovich A. H., Weisdorf D., Pavletic S. et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease:Filipovich A. H., Weisdorf D., Pavletic S. et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease:I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11(12):945–56.I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11(12):945–56.Socie G. Chronic GVHD: a new risk score? Blood 2011;117(24):6408–9.Socie G. Chronic GVHD: a new risk score? Blood 2011;117(24):6408–9.Pavletic S., Lee S., Socie G., Vogelsang G. Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials. Bone Marrow Transplant 2006;38(10):645–51.Pavletic S., Lee S., Socie G., Vogelsang G. Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials. Bone Marrow Transplant 2006;38(10):645–51.Sullivan K. M. Graft-versus-Host disease. In: Bone marrow transplantation; Forman S. J., Blume K. G., Thomas E. D. (eds.). Blackwell Scientific Publications: Boston, 1994. Pp. 339–362.Sullivan K. M. Graft-versus-Host disease. In: Bone marrow transplantation; Forman S. J., Blume K. G., Thomas E. D. (eds.). Blackwell Scientific Publications: Boston, 1994. Pp. 339–362.Zecca M., Prete A., Rondelli R. et al. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood 2002;100(4):1192–200.Zecca M., Prete A., Rondelli R. et al. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood 2002;100(4):1192–200.Atkinson K., Horowitz M. M., Gale R. P. et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990;75:2459–64.Atkinson K., Horowitz M. M., Gale R. P. et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990;75:2459–64.Vogelsang G. B. Chronic graft versus host disease. Br J Hematol 2004;125:435–54.Vogelsang G. B. Chronic graft versus host disease. Br J Hematol 2004;125:435–54.Schubert M. M., Sullivan K. M., Morton T. H. et al. Oral manifestations of chronic graft-versus-host disease. Arch Intern Med 1984;144:1591–5.Schubert M. M., Sullivan K. M., Morton T. H. et al. Oral manifestations of chronic graft-versus-host disease. Arch Intern Med 1984;144:1591–5.Akpek G., Chinratanalab W., Lee L. et al. Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study. Biol Blood Marrow Transplant 2003;9:46–51.Akpek G., Chinratanalab W., Lee L. et al. Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study. Biol Blood Marrow Transplant 2003;9:46–51.Lee S. J., Vogelsang G., Flowers M. et al. Chronic graft-versus-host disease. New York: American Society for Blood and Marrow Transplantation, 2003.Lee S. J., Vogelsang G., Flowers M. et al. Chronic graft-versus-host disease. New York: American Society for Blood and Marrow Transplantation, 2003.Greinix H. T., Socie G., Bacigalupo A. et al. Assessing the potential roleGreinix H. T., Socie G., Bacigalupo A. et al. Assessing the potential roleof photopheresis in hematopoietic stem cell transplant. Bone Marow Transplant 2006;38(4):265–73.of photopheresis in hematopoietic stem cell transplant. Bone Marow Transplant 2006;38(4):265–73.Robin M., Guardiola P., Girinsky T. et al. Low-dose thoracoabdominal irradiationRobin M., Guardiola P., Girinsky T. et al. Low-dose thoracoabdominal irradiationfor the treatment of refractory chronic graft-versus-host disease. Transplantation 2005;80(5):634–42.for the treatment of refractory chronic graft-versus-host disease. Transplantation 2005;80(5):634–42.Syrjala K. L., Langer S. L., Abrams J. R. et al. Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol 2005;23(27):6596–606.Syrjala K. L., Langer S. L., Abrams J. R. et al. Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol 2005;23(27):6596–606.Cohen A., Békássy A. N., Gaiero A. et al. Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Transplant 2008; 41 Suppl 2:S43–8.Cohen A., Békássy A. N., Gaiero A. et al. Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Transplant 2008; 41 Suppl 2:S43–8.Faraci M., Barra S., Cohen A. et al. Very late nonfatal consequencies of fractionated TBI in children undergoing bone marrow transplant. Int J Radiat Oncol Biol Phys 2005;63(5):1568–75.Faraci M., Barra S., Cohen A. et al. Very late nonfatal consequencies of fractionated TBI in children undergoing bone marrow transplant. Int J Radiat Oncol Biol Phys 2005;63(5):1568–75.Salooja N., Szydlo R. M., Socie G. et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet 2001;358:271–6.Salooja N., Szydlo R. M., Socie G. et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet 2001;358:271–6.Brennan B. M., Shalet S. M. Endocrine late effects after bone marrow transplant. Br J Haematol 2002;118:58–66.Brennan B. M., Shalet S. M. Endocrine late effects after bone marrow transplant. Br J Haematol 2002;118:58–66.Patriarca F., Skert C., Bonifazi F. et al. Effect on survival of the development of late-onset non-infectious pulmonary complications after stem cell transplantation. Haematologica 2006;91(9):1268–72.Patriarca F., Skert C., Bonifazi F. et al. Effect on survival of the development of late-onset non-infectious pulmonary complications after stem cell transplantation. Haematologica 2006;91(9):1268–72.Palmas A., Tefferi A., Myers J. L. et al. Late-onset non-infectious pulmonary complications after allogeneic bone marrow transplantation. Br J Hematol 1998;100:680–7.Palmas A., Tefferi A., Myers J. L. et al. Late-onset non-infectious pulmonary complications after allogeneic bone marrow transplantation. Br J Hematol 1998;100:680–7.Faraci M., Békássy A. N., De Fazio V.Faraci M., Békássy A. N., De Fazio V.et al. Non-endocrine late complications in children after allogeneic haematopoietic SCT. Bone Marrow Transplant 2008;41:S49–57.et al. Non-endocrine late complications in children after allogeneic haematopoietic SCT. Bone Marrow Transplant 2008;41:S49–57.Tichelli A., Gratwohl A., Egger T. et al. Cataract formation after bone marrow transplantation. Ann Intern Med 1993;119(12):1175–80.Tichelli A., Gratwohl A., Egger T. et al. Cataract formation after bone marrow transplantation. Ann Intern Med 1993;119(12):1175–80.Tichelli A., Duell T., Weiss M. et al. Late-onset keratoconjunctivitis sicca syndrome after bone marrow transplantation: incidence and risk factors. European Group or Blood and Marrow Transplantation (EBMT) Working Party on Late Effects. Bone Marrow Transplant 1996;17(6):1105–11.Tichelli A., Duell T., Weiss M. et al. Late-onset keratoconjunctivitis sicca syndrome after bone marrow transplantation: incidence and risk factors. European Group or Blood and Marrow Transplantation (EBMT) Working Party on Late Effects. Bone Marrow Transplant 1996;17(6):1105–11.Socie G., Cahn J. Y., Carmelo J. et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Société Française de Greffe de Moëlle (SFGM). Br J Hematol 1997;97(4):865–70.Socie G., Cahn J. Y., Carmelo J. et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Société Française de Greffe de Moëlle (SFGM). Br J Hematol 1997;97(4):865–70.

The authors declare that there are no conflicts of interest present.